TESCREAL
LongevityOct 23, 2026

Embryo Screening and the Future of Parental Choice

Genetic testing in IVF is expanding from disease checks to polygenic reports on health risks and traits, giving parents more information when choosing which embryo to transfer.

Share:
Micromanipulation of an embryo under laboratory instruments

From disease screening to trait prediction

For decades, genetic testing during pregnancy and IVF has largely focused on identifying serious inherited conditions. Parents with a family history of cystic fibrosis, for example, could test embryos to determine which ones carried the mutation. Newer genetic screening companies are offering something broader: reports that compare embryos based on predicted health risks and traits such as height, intelligence, and physical appearance.

The shift is changing the questions prospective parents can ask before pregnancy begins. Instead of looking only for a specific inherited disorder, they can receive genetic estimates across a much wider range of characteristics and use that information when deciding which embryo to transfer.

Nucleus Genomics brought this idea into public view in 2025 with the launch of Nucleus Embryo. Its advertising campaign drew attention because it presented embryo selection in terms that went well beyond disease prevention. Parents were shown comparisons involving IQ, height, eye color, hair color, and other characteristics. The company was offering a service that treated genetic information as a way to compare the potential traits of future children, not simply to identify serious medical conditions.

Embryo testing is already a standard part of many IVF processes. After fertilization, embryos are grown in a laboratory until they reach the blastocyst stage. An embryologist can then remove a small sample of cells from the outer layer of each embryo. The sample is sent for genetic analysis while the embryos are frozen or otherwise prepared for later transfer.

Traditional testing includes several different methods. PGT-A checks whether an embryo has the expected number of chromosomes. PGT-M looks for a specific single-gene condition known to run in a family. These tests answer relatively defined questions: whether an embryo has a chromosomal abnormality or carries a particular disease-causing mutation.

Polygenic embryo screening takes a different approach. Many common conditions and human characteristics are influenced by thousands of genetic variants, each contributing a small amount to the overall result. Companies analyze these variants and combine their estimated effects into a polygenic score. The resulting report can compare embryos for predispositions to conditions such as heart disease or diabetes, as well as traits including height and cognitive ability.

This is a different proposition from testing for a known inherited mutation. A polygenic score does not identify a single gene that determines a characteristic. It estimates how an embryo’s collection of genetic variants compares with those of other people in the reference data used to build the model. The result is a probability-based estimate, not a guaranteed description of a future child.

For parents, the appeal is the ability to compare several embryos from the same IVF cycle. If multiple embryos are suitable for transfer, genetic reports may provide additional information to consider. One family might place the greatest importance on reducing inherited disease risks. Another might also want to consider predicted height or cognitive traits.

The companies building the technology

Nucleus Genomics has become one of the most visible companies in this market. Its Nucleus Embryo service combines genetic screening with embryo comparisons covering health and selected physical and cognitive traits. The company’s current materials advertise predictions involving height, IQ, and BMI, alongside disease-risk information and characteristics such as eye color. In September 2026, Nucleus published research describing its newer Vitruvian models for height, BMI, and intelligence. The company says these models use millions of genetic variants together with functional genomic information to improve predictions within families.

Nucleus has also continued developing its broader consumer genetics platform. Its embryo service is part of a larger effort to make genetic information available before conception and during IVF. The company’s approach reflects a shift in how genetic testing is marketed. Rather than presenting results only as medical findings, it presents them as information parents can use to compare possible outcomes.

Herasight is another company working on polygenic embryo screening. Its services have been marketed around predictions for intelligence, height, longevity, and health risks. Its approach uses genetic scores to compare embryos across complex traits, including characteristics that are influenced by many genes rather than a single inherited mutation. Herasight’s work is part of a growing effort to turn large genetic datasets into reports that can be used in reproductive decisions.

Orchid Health takes a broader whole-genome approach, with a stronger emphasis on disease screening. The company says its embryo report sequences more than 99 percent of an embryo’s genome and screens for more than 1,700 single-gene disorders. It also offers polygenic risk scores for selected common conditions. Orchid’s reports can include information about hereditary cancers, neurodevelopmental disorders, birth defects, and adult-onset diseases, alongside chromosome screening.

Orchid’s service illustrates how quickly the amount of genetic information available from an embryo sample is increasing. Rather than ordering separate tests for a small number of known conditions, parents can receive a much wider report from the same biopsy used in conventional embryo testing. Its emphasis is primarily on health, but its use of whole-genome sequencing is part of the same broader movement toward more detailed embryo profiles.

Genomic Prediction is another important name in the field. Its LifeView platform helped bring polygenic embryo screening into commercial use, and the company has worked with Nucleus on embryo testing. Its technology analyzes genetic variants associated with complex diseases and traits, then uses statistical models to estimate relative risks. Together, these companies are helping move embryo testing from targeted screening toward broader genetic comparisons.

What parents may be able to choose

The traits attracting attention fall into several categories. Health risks are one of the most immediate applications. Parents may want to compare embryos for genetic predispositions to heart disease, diabetes, certain cancers, or other common conditions. A report could help identify embryos with relatively lower estimated risk for a particular condition, giving families another factor to consider alongside chromosome results and other medical information.

Physical traits are also part of the market. Height is a prominent example because it is strongly influenced by genetics and can be estimated using large collections of genetic variants. Companies have also advertised predictions involving eye color and hair color. These characteristics are more familiar to consumers than polygenic risk scores, which makes them an easy way to explain what genetic comparison might look like.

Cognitive traits are a more consequential area of development. Nucleus and Herasight have both brought intelligence prediction into their public-facing services. These estimates are based on genetic patterns associated with measured cognitive outcomes in research populations. They do not provide a fixed IQ for a future child, but companies are working to estimate relative differences between embryos using the genetic information available.

Other possible areas include expected body mass index, longevity, and behavioral or neurological characteristics. As genetic databases expand and prediction models improve, companies may offer parents a wider set of comparisons. Some of these traits are already part of commercial offerings, while others remain less developed or are being studied as potential applications.

The larger change is that parents may increasingly have access to genetic profiles that cover far more than a short list of inherited diseases. IVF already involves decisions about which embryos to transfer. More comprehensive genetic reports add another source of information to those decisions, giving parents the ability to weigh health risks and predicted characteristics according to their own priorities.

Published: Oct 23, 2026